GB1107 (GB-1107) is a novel, potent, selective, orally bioavailable galectin-3 (GAL-3) inhibitor with anticancer activity. IT inhibits GAL-3 with a Kd of 37 nM. GB1107 inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade. GB1107 reduces human and mouse lung adenocarcinoma growth and blocks metastasis in the syngeneic model.

纯度：≥98%

CAS：1978336-61-6